In its latest annual report and statistical release, the European Patent Office (EPO) noted a significant increase in the volume of patents being filed in the pharmaceutical and biotechnology sectors, both from here in the UK and from other leading economies. The EPO annual report, published in March 2018, shows a significant rise in patents filed by UK companies across both sectors in 2017 – with biotech up 25.3% and pharma up 15.7%.
UK companies which file at the EPO can protect their inventions across the EPO’s 38 member states.
The latest analysis from the EPO would indicate that biotech and pharmaceuticals are clearly growth industries both here in the UK and worldwide. Underpinning this growth are greater levels of research and development (R&D) and a greater awareness of the need to file for patent protection to protect the fruits of that research and the money invested in it.
Biotech and pharma research is extremely expensive, so the growth in filings suggests that the funding streams and investment are growing at a much higher rate than they were previously.
The global crash from 2007-2009 put a huge damper on investment in all areas, so it may be we are now seeing signs that we have come out of that to some extent and there is more confidence in investing. It will be interesting to see if this is a blip or if this is the new benchmark, but either way, it certainly suggests the innovation is out there.
The UK was not the only area to report a rise in these sectors – the picture was reflected across the globe. The total number of patent filings at the EPO for biotech and pharma was up 14.5% and 8.1% respectively.
This year, medical technology topped the list of the ten leading fields of technology in 2017 with 13,090 applications. Pharmaceuticals ranked eighth with 6,330 applications, while biotechnology ranked ninth with 6,278 applications.
Data source: EPO Annual Report 2017.
Written by Will Arends, Partner at Marks & Clerk.
Feature image © Fotoschlick – stock.adobe.com